Adalimumab Market – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:05 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Adalimumab Market – CRI Report https://www.cri-report.com 32 32 Investigation Report on Chinese Adalimumab Market, 2021-2025 https://www.cri-report.com/investigation-report-on-chinese-adalimumab-market-2021-2025/ Sat, 10 Apr 2021 06:25:25 +0000 https://www.cri-report.com/?post_type=product&p=10968 According to CRI’s market research, in China, the sales of Adalimumab increased significantly in 2020, reaching approximately CNY 101.11 million (2019 sales revenue is CNY 14.15 million), and the CAGR is around 38% from 2016 to 2020.

The post Investigation Report on Chinese Adalimumab Market, 2021-2025 first appeared on CRI Report.

]]> In 2010, Adalimumab entered the Chinese market. Its original drug is produced by AbbVie Inc., under the brand name HUMIRA. The sales of HUMIRA is ranking at Top one among all pharmaceutical products since it is used for a huge amount of disease treatments (such as treatment of arthritis, Crohn’s disease, ulcerative colitis, and so on). However, unlike the EU and the NA market, Adalimumab is not popular in the Chinese market. From 2016 to 2019, the sales of Adalimumab decreased gradually due to three reasons. One is because it is not included in the medical insurance, while its price is about CNY7,600 per injection, which makes a patient spend about CNY10,000 to CNY20,000 on the medicine. Secondly, Adalimumab has far fewer indications approved in China than that in the EU and the NA countries (including the indications for rheumatoid arthritis approved in 2010, the indications for ankylosing spondylitis approved in 2013, and the indications for psoriasis approved in 2017). Lastly, adjuvant drugs have dominated the Chinese drug sales market for a long period.

On the other hand, after the declining sales from 2016 to 2019, the sales of Adalimumab in the Chinese market have increased by about 7 times in 2020 compared to the previous year. The substantial increase is mainly due to the improvement of medical insurance policies and the rectification of the abuse of adjuvant drugs. Besides, more generic drugs appear in the market since the patent of HUMIRA is about to expire. Although Abbvie Inc. successfully postponed the threat of US biosimilars to 2023, it lost its patent protection in Europe on October 16, 2018. In China, 28 companies have filed generic drug applications for Adalimumab biosimilars in 2019. In 2020, three companies have launched generic drugs, namely Zhejiang Hisun Pharmaceutical Co., Ltd., Bio-Thera Solutions, Ltd., and Innovent Biologics (Suzhou) Co., Ltd.

According to CRI’s market research, in China, the sales of Adalimumab increased significantly in 2020, reaching approximately CNY 101.11 million (2019 sales revenue is CNY 14.15 million), and the CAGR is around 38% from 2016 to 2020. Therefore, CRI analyzes that with the emergence of generic drugs, the choice of drugs increases. Therefore, the price of drugs will decrease. Coupled with the strict control of adjuvant drugs and the improvement of medical insurance policies, Adalimumab is expected to be more popular in China in 2021-2025, and sales will also increase accordingly.

Topics Covered:
-The impact of COVID-19 on China’s adalimumab market
– Sales value and volume of China’s adalimumab 2016-2020
– Competitive landscape of China’s adalimumab market
– Prices of adalimumab in China
– Prices of adalimumab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s adalimumab market
– Prospect of China’s adalimumab market from 2021 to 2025

The post Investigation Report on Chinese Adalimumab Market, 2021-2025 first appeared on CRI Report.

]]>